enerzair breezhaler 114 mcg46 mcg136 mcg
novartis israel ltd - glycopyrronium as bromide; indacaterol as acetate; mometasone furoate - hard capsule - mometasone furoate 160 mcg; glycopyrronium as bromide 50 mcg; indacaterol as acetate 150 mcg - mometasone - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.important limitations of use:enerzair breezhaler is not indicated in patients with copd.
zimbus breezhaler 114/46/68 indacaterol/glycopyrronium/mometasone furoate 114/46/68 microgram powder for inhalation in capsule with inhaler
grand medical pty ltd - glycopyrronium bromide, quantity: 63 microgram (equivalent: glycopyrronium, qty 50 microgram); mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate - zimbus breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
bemrist breezhaler 125/62.5 indacaterol (as acetate)/mometasone furoate 125/62.5 microgram powder for inhalation in hard capsule with inhaler
grand medical pty ltd - mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - bemrist breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists
atectura breezhaler 125/62.5 indacaterol (as acetate)/mometasone furoate 125/62.5 microgram powder for inhalation in hard capsule with inhaler
novartis pharmaceuticals australia pty ltd - mometasone furoate, quantity: 80 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists
bemrist breezhaler 125/127.5 indacaterol (as acetate)/mometasone furoate 125/127.5 mcg powder for inhalation in hard capsule with inhaler
grand medical pty ltd - mometasone furoate, quantity: 160 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - bemrist breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists
atectura breezhaler 125/127.5 indacaterol (as acetate)/mometasone furoate 125/127.5 mcg powder for inhalation in hard capsule with inhaler
novartis pharmaceuticals australia pty ltd - mometasone furoate, quantity: 160 microgram; indacaterol acetate, quantity: 173 microgram (equivalent: indacaterol, qty 150 microgram) - capsule, hard - excipient ingredients: lactose monohydrate - atectura breezhaler is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older where use of a combination of long-acting beta2-agonist and inhaled corticosteroid is appropriate:,- patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists or,- patients not adequately controlled with long-acting beta2-agonists and low dose of inhaled corticosteroids and "as needed" inhaled short-acting beta2-agonists
enerzair breezhaler (indacaterol acetateglycopyrronium bromidemometasone furoate) 1505080mcg inhalation powder hard capsules
novartis corporation (malaysia) sdn. bhd. - mometasone furoate; indacaterol acetate; glycopyyronium bromide -
ultibro breezhaler capsule
novartis pharmaceuticals canada inc - glycopyrronium (glycopyrronium bromide); indacaterol (indacaterol maleate) - capsule - 50mcg; 110mcg - glycopyrronium (glycopyrronium bromide) 50mcg; indacaterol (indacaterol maleate) 110mcg - antimuscarinics antispasmodics
atectura breezhaler inhalation powder hard capsule 150 mcg 160 mcg
novartis (singapore) pte ltd - indacaterol acetate equivalent to indacaterol; mometasone furoate - powder, metered - indacaterol acetate equivalent to indacaterol 150 mcg; mometasone furoate 160 mcg
atectura breezhaler inhalation powder hard capsule 150 mcg 320 mcg
novartis (singapore) pte ltd - indacaterol acetate equivalent to indacaterol; mometasone furoate - powder, metered - indacaterol acetate equivalent to indacaterol 150 mcg; mometasone furoate 320 mcg